Results 1 to 10 of about 45,597 (259)

7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir. [PDF]

Angew Chem Int Ed Engl, 2018
Ziegler RE, Desai BK, Jee JA, Gupton BF, Roper TD, Jamison TF.   +5 more
europepmc   +3 more sources

Novel DNA Biosensing Platform for Detecting HIV Integrase for Highly Sensitive and Quantitative HIV Detection, Diagnosis, and Therapeutic Monitoring. [PDF]

ACS Omega
Chen F, Wang J, Ma J, Song L, Yan H, Wang F, Yang Z, Li F.   +7 more
europepmc   +2 more sources

HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa. [PDF]

PLoS ONE, 2011
Antiretroviral therapy for HIV-2 infection is hampered by intrinsic resistance to many of the drugs used to treat HIV-1. Limited studies suggest that the integrase inhibitors (INIs) raltegravir and elvitegravir have potent activity against HIV-2 in ...
Geoffrey S Gottlieb, Robert A Smith, Ndeye Mery Dia Badiane, Selly Ba, Stephen E Hawes, Macoumba Toure, Alison K Starling, Fatou Traore, Fatima Sall, Stephen L Cherne, Joshua Stern, Kim G Wong, Paul Lu, Moon Kim, Dana N Raugi, Airin Lam, James I Mullins, Nancy B Kiviat, Papa Salif Sow for the UW-Dakar HIV-2 Study Group   +18 more
doaj   +1 more source

Small molecule inhibitors of the LEDGF site of human immunodeficiency virus integrase identified by fragment screening and structure based design. [PDF]

PLoS ONE, 2012
A fragment-based screen against human immunodeficiency virus type 1 (HIV) integrase led to a number of compounds that bound to the lens epithelium derived growth factor (LEDGF) binding site of the integrase catalytic core domain.
Thomas S Peat, David I Rhodes, Nick Vandegraaff, Giang Le, Jessica A Smith, Lisa J Clark, Eric D Jones, Jonathan A V Coates, Neeranat Thienthong, Janet Newman, Olan Dolezal, Roger Mulder, John H Ryan, G Paul Savage, Craig L Francis, John J Deadman   +15 more
doaj   +1 more source

Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor. [PDF]

PLoS ONE, 2015
Understanding the HIV integrase protein and mechanisms of resistance to HIV integrase inhibitors is complicated by the lack of a full length HIV integrase crystal structure. Moreover, a lentiviral integrase structure with co-crystallised DNA has not been
Peter K Quashie, Ying-Shan Han, Said Hassounah, Thibault Mesplède, Mark A Wainberg   +4 more
doaj   +1 more source

Integrase deficient lentiviral vector: prospects for safe clinical applications [PDF]

PeerJ, 2022
HIV-1 derived lentiviral vector is an efficient transporter for delivering desired genetic materials into the targeted cells among many viral vectors. Genetic material transduced by lentiviral vector is integrated into the cell genome to introduce new ...
Chee-Hong Takahiro Yew, Narmatha Gurumoorthy, Fazlina Nordin, Gee Jun Tye, Wan Safwani Wan Kamarul Zaman, Jun Jie Tan, Min Hwei Ng   +6 more
doaj   +2 more sources

The Discovery of Indole-2-carboxylic Acid Derivatives as Novel HIV-1 Integrase Strand Transfer Inhibitors

Molecules, 2023
As an important antiviral target, HIV-1 integrase plays a key role in the viral life cycle, and five integrase strand transfer inhibitors (INSTIs) have been approved for the treatment of HIV-1 infections so far.
Yu-Chan Wang, Wen-Li Zhang, Rong-Hong Zhang, Chun-Hua Liu, Yong-Long Zhao, Guo-Yi Yan, Shang-Gao Liao, Yong-Jun Li, Meng Zhou   +8 more
doaj   +1 more source

Targeting the Integrated Stress Response Kinase GCN2 to Modulate Retroviral Integration

Molecules, 2021
Multiple viral targets are now available in the clinic to fight HIV infection. Even if this targeted therapy is highly effective at suppressing viral replication, caregivers are facing growing therapeutic failures in patients due to resistance, with or ...
Chloé Torres, Asja Garling, Saïd Taouji, Christina Calmels, Marie-Line Andreola, Mathieu Métifiot   +5 more
doaj   +1 more source

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. [PDF]

PLoS ONE, 2012
Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a
Robert A Smith, Dana N Raugi, Charlotte Pan, Matthew Coyne, Alexandra Hernandez, Brad Church, Kara Parker, James I Mullins, Papa Salif Sow, Geoffrey S Gottlieb, University of Washington-Dakar HIV-2 Study Group   +10 more
doaj   +1 more source

Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. [PDF]

, 2020
IntroductionWeight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio-metabolic disease.
Altoff, Keri N, Bourgi, Kassem, Crane, Heidi, Gange, Stephen J, Gill, John, Horberg, Michael A, Jenkins, Cathy A, Kirk, Gregory, Koethe, John R, Lake, Jordan, Li, Jun, Lima, Viviane D, Margolick, Joseph, Mathews, William C, Moore, Richard D, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Palella, Frank, Rabkin, Charles S, Rebeiro, Peter F, Silverberg, Michael, Sterling, Timothy R, Thorne, Jennifer, Willig, Amanda, Wong, Cherise   +23 more
core   +1 more source